Fig. 6
EO cells decrease breast cancer proliferation in vitro. MDA-MB-231, MDA-MB-231BRMS, or MCF-7 cells were plated at 1 × 105 cells/cm2 in 35 × 10 mm dishes, then treated with either MC3T3-E1 CM, CM from cancer cells of the same type (e.g., MDA-MB-231 cells treated with MDA-MB-231 cell CM), or corresponding EO cell variant (e.g., MDA-MB-231 cells treated with EO-231 CM). Three individual replicates per time point per condition were plated. On days 1, 2, 3, 4, and 5, cancer cells were detached and counted using a hemocytometer. a MDA-MB-231 cells treated with either MC3T3-E1, MDA-MB-231, or EO-231 CM. b MDA-MB-231BRMS cells treated with either MC3T3-E1, MDA-MB-231BRMS, or EO-BRMS CM. c MCF-7 cells treated with either MC3T3-E1, MCF-7, or EO-MCF7 CM. *P < 0.05 MC3T3-E1 CM treatment vs. EO CM treatment; #P < 0.05 cancer cell CM treatment vs. EO CM treatment. N = 3 per condition, per time point